Retlirafusp Alfa

DRUG3 trials

Sponsors

Tang-Du Hospital

Conditions

Esophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaPancreatic Cancer

Phase 2

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Not yet recruitingNCT07618910

Tang-Du HospitalEsophageal Squamous Cell Carcinoma

Start: 2026-05-30End: 2028-05-30Target: 33Updated: 2026-06-01

Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07709767

Tang-Du HospitalGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2026-08-30End: 2032-08-30Target: 21Updated: 2026-07-17

Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer

Not yet recruitingNCT07773363

Tang-Du HospitalPancreatic Cancer

Start: 2026-08-30End: 2028-12-30Target: 37Updated: 2026-08-19